Delivery Order SPE2DB20D3505-SPE2DB25FV0C7
- Not listed
- The Defense Logistics Agency awarded a $11.89K delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed price, non-set-aside contract with a completion date of July 24, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder, reflecting the Defense Logistics Agency's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $2,384.16 to AmerisourceBergen Drug Corp for CAPLYTA (lumateperone) 21 mg capsules (quantity: 30) on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units) under a firm fixed-price contract valued at $16,991.12. This non-competitive delivery order was issued on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment...
- The Defense Logistics Agency awarded a $14,646.30 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of CAPLYTA 42 mg capsules (30-count units). This is a firm fixed-price, non-set-aside contract with a completion deadline of June 3, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. CAPLYTA is a prescription antipsychotic medication used in the treatment of schizophrenia and bipolar depression, representing the type of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units) with a ceiling value of $1,943.32. This non-set-aside, firm fixed-price delivery order is scheduled for completion by June 6, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. CAPLYTA (lumateperone) is an atypical antipsychotic medication used in the treatment of schizophrenia and...
- The Defense Logistics Agency awarded a $22,965.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of CAPLYTA 10.5 mg capsules (quantity: 30 units). This is a competitively awarded contract with no set-aside designation, with performance to be completed by September 4, 2025, and fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units). This firm fixed-price delivery order, valued at $4,321.91, represents a non-set-aside award issued through competitive procurement. The contract is set for ultimate completion on August 8, 2025, with performance taking place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. CAPLYTA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 10.5 mg capsules (30-count units) with a ceiling value of $2,835.01. This competitive award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this order. The award falls under the company's...
- The Defense Logistics Agency awarded a delivery order valued at $3,351.92 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract valued at $10,226.69. The award was made on July 24, 2025, with an ultimate completion date of July 25, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FV0C7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,210.29 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on July 18, 2025, with completion anticipated by July 21, 2025. This firm fixed price delivery order carries no set-aside designation and represents a competitive award to the prime contractor based in Conshohocken, Pennsylvania. CAPLYTA is an atypical antipsychotic medication used in the treatment of schizophrenia and bipolar disorder, reflecting the pharmaceutical supply needs of military and defense healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026 that supports global pharmaceutical procurement for military healthcare programs. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor providing comprehensive medical supplies, brand-name and generic medications, vaccines, and specialized healthcare commodities to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill federal procurement requirements across diverse therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 7/18/25 |